Bhargava has experience leading the CC@IL, having served as faculty coordinator for the past four years. As director, he will spearhead efforts to unite researchers in the effort to find better ways to prevent, detect, diagnose, and treat cancer.
Earlier this year, the National Cancer Institute (NCI) of the National Institutes of Health (NIH) awarded a grant totalling more than $1.6M to Bhargava and Beckman researchers in his lab. 3D Prostate Histochemometry to Predict Disease Recurrence proposes a new chemical imaging technology to determine the risk of lethal prostate cancer upon initial diagnosis, with the goal of preventing over-treatment.